B7-1 and B7-2 act differentially in the induction of a T cell response: Their impact for a HLA-matched and HLA-mismatched anti-tumor immunotherapy

International Journal of Cancer

Volumn 117, Issue 5, 2005, Pages 794-799

  Kronfeld, Kai ^a   Abken, Hinrich ^b,c   Seliger, Barbara ^a,d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

B7; Co stimulation; HLA Class I mismatch; Immunotherapy

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HLA MATCHING; HLA SYSTEM; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MIXED LYMPHOCYTE CULTURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TISSUE CULTURE;

ANTIGENS, CD80; ANTIGENS, CD86; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; LYMPHOCYTE CULTURE TEST, MIXED; T-LYMPHOCYTES;

EID: 27744588820     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21230     Document Type: Article

References (27)

1. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001;1:220-8.
2. Collins AV, Brodie DW, Gilbert RJ, Iaboni A, Manso-Sancho R, Walse B, Stuart DI, van der Merwe PA, Davis SJ. The interaction properties of costimulatory molecules revisited. Immunity 2002;17:201-10.
3. Pentcheva-Hoang T, Egen JG, Wojnoonski K, Allison JP. B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity 2004;21:401-13.
4. Suresh M, Whitmire JK, Harrington LE, Larsen CP, Pearson TC, Altman JD, Ahmed R. Role of CD28-B7 interactions in generation and maintenance of CD8 T cell memory. J Immunol 2001;167:5565-73.
5. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002;2:116-26.
6. Chaperot L, Plumas J, Jacob MC, Bost F, Molens JP, Sotto JJ, Bensa JC. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp Hematol 1999;27:479-88.
7. Imro MA, Dellabona P, Manici S, Heltai S, Consogno G, Bellone M, Rugarli C, Protti MP. Human melanoma cells transfected with the B7-2 co-stimulatory molecule induce tumor-specific CD8+ cytotoxic T lymphocytes in vitro. Hum Gene Ther 1998;9:1335-44.
8. Jung D, Hilmes C, Knuth A, Jaeger E, Huber C, Seliger B. Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent. Scand J Immunol 1999;50:242-9.
9. Emtage PC, Wan Y, Bramson JL, Graham FL, Gauldie J. A double recombinant adenovirus expressing the costimulatory molecule B7-1 (murine) and human IL-2 induces complete tumor regression in a murine breast adenocarcinoma model. J Immunol 1998;160:2531-8.
10. Stremmel C, Greenfield EA, Howard E, Freeman GJ, Kuchroo VK. B7-2 expressed on EL4 lymphoma suppresses antitumor immunity by an interleukin 4-dependent mechanism. J Exp Med 1999;189:919-30.
11. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-93.
12. Schendel DJ, Frankenberger B, Jantzer P, Cayeux S, Nobetaner E, Willimsky G, Maget B, Pohla H, Blankenstein T. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther 2000;7:2007-14.
13. Bain C, Merrouche Y, Puisieux I, Due A, Colombo MP, Favrot M. B7.1 gene transduction of human renal-cell-carcinoma cell lines restores the proliferative response and cytotoxic function of allogeneic T cells. Int J Cancer 1996;67:769-76.
14. Antonia SJ, Seigne JD. B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma. World J Urol 2000;18:157-63.
15. Schendel DJ, Obemeder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmuller G, Nossner E. Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 1997;75:400-13.
16. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
17. Finke JH, Rayman P, Edinger M, Tubbs RR, Stanley J, Klein E, Bukowski R. Characterization of a human renal cell carcinoma specific cytotoxic CD8+ T cell line. J Immunother 1992;11:1-11.
18. Bernhard H, Karbach J, Wolfel T, Busch P, Storkel S, Stockle M, Wolfel C, Seliger B, Huber C, Meyer, zum Buschenfelde KH, Knuth A. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 1994;59:837-42.
19. Seliger B, Hohne A, Jung D, Kallfelz M, Knuth A, Jaeger E, Bernhard H, Momburg F, Tampe R, Huber C. Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. Exp Hematol 1997;25:608-14.
20. Salomon B, Bluestone JA. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 2001;19:225-52.
21. Matulonis U, Dosiou C, Freeman G, Lamont C, Mauch P, Nadler LM, Griffin JD. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol 1996;156:1126-31.
22. Vasilevko V, Ghochikyan A, Holterman MJ, Agadjanyan MG. CD80 (B7-1) and CD86 (B7-2) are functionally equivalent in the initiation and maintenance of CD4+ T-cell proliferation after activation with suboptimal doses of PHA. DNA Cell Biol 2002;21:137-49.
23. Smythe JA, Fink PD, Logan GJ, Lees J, Rowe PB, Alexander IE. Human fibroblasts transduced with CD80 or CD86 efficiently transcostimulate CD4+ and CD8+ T lymphocytes in HLA-restricted reactions: implications for immune augmentation cancer therapy and auto-immunity. J Immunol 1999;163:3239-49.
24. Fields PE, Finch RJ, Gray GS, Zollner R, Thomas JL, Sturmhoefel K, Lee K, Wolf S, Gajewski TF, Fitch FW. B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells. J Immunol 1998;161:5268-75.
25. Matsumoto K, Anasetti C. The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia. Leuk Lymphoma 1999;35:427-35.
26. Horig H, Lee DS, Conkright W, Divito J, Hasson H, LaMare M, Rivera A, Park D, Tine J, Guito K, Tsang KW, Schlom J, et al. Phase I clinical trial of a recombinant canary poxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol Immunother 2000;49:504-14.
27. Meyer GC, Batrla R, Rudy W, Meuer SC, Wallwiener D, Guckel B, Moebius U. Potential of CD80-transfected human breast carcinoma cells to induce peptide-specific T lymphocytes in an allogeneic human histocompatibility leukocyte antigens (HLA)-A2.1+-matched situation. Cancer Gene Ther 1999;6:282-8.